Related Experiment Video
Updated: Feb 6, 2026

Author Spotlight: Implementation of BIVA for Analyzing Disease Risk Factors in Patients with Low Body Cell Mass
Published on: July 14, 2023
Azilsartan improves the effects of etanercept in patients with active rheumatoid arthritis: a pilot study
Naza Mohammed Ali Mahmood1, Saad Abdulrahman Hussain2, Raouf Rahim Mirza3
1Department of Pharmacology and Toxicology, College of Pharmacy, University of Sulaimani, Kurdistan Region, Iraq.
Background And Aim:
Much evidence has emerged documenting the involvement of the renin-angiotensin system (RAS) in inflammatory processes. The objective of this study was to evaluate the effects of blocking RAS with azilsartan (Azil) on the clinical efficacy of etanercept (Etan) in patients with active rheumatoid arthritis (RA).
Patients And Methods:
Forty-two patients diagnosed with active RA and poorly responding to methotrexate were enrolled in this pilot clinical study. They were randomly allocated into two groups, and treated with either Etan (50 mg/week) and placebo or the same dose of Etan with Azil (20 mg/day) for 90 days. The clinical outcome was evaluated using the Disease Activity Score-28 joint (DAS-28), simplified disease activity index (SDAI), clinical disease activity index (CDAI) and the health assessment questionnaire disease index (HAQ-DI). Blood samples were obtained for the assessment of C-reactive protein and erythrocyte sedimentation rate at baseline and after 90 days.
Results:
The markers of pain and disease activity, C-reactive protein and erythrocyte sedimentation rate were significantly improved when Azil was used, as an adjuvant with Etan, compared with the use of Etan and placebo.
Conclusion:
Blocking RAS with azilsartan may improve the effects of etanercept on the clinical markers of pain and disease severity of patients with active RA not responding to methotrexate.
Insights
Adding azilsartan to etanercept significantly improved pain and disease activity markers in rheumatoid arthritis patients. Blocking the renin-angiotensin system (RAS) with azilsartan enhanced etanercept
Area of Science:
- Immunology
- Rheumatology
- Pharmacology
Background:
- The renin-angiotensin system (RAS) is implicated in inflammatory processes.
- Rheumatoid arthritis (RA) involves chronic inflammation and immune system dysregulation.
Purpose of the Study:
- To investigate the impact of azilsartan (Azil), a RAS blocker, on the clinical effectiveness of etanercept (Etan) in active RA patients.
- To assess if combining Azil with Etan improves treatment outcomes compared to Etan alone.
Main Methods:
- A pilot study involved 42 RA patients with inadequate response to methotrexate.
- Patients received either Etan (50 mg/week) plus placebo or Etan plus Azil (20 mg/day) for 90 days.
- Disease activity was measured using DAS-28, SDAI, CDAI, and HAQ-DI; inflammatory markers (CRP, ESR) were also assessed.
Main Results:
- Combination therapy with Etan and Azil resulted in significant improvements in pain and disease activity markers.
- Key indicators such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) showed marked reduction with Azil co-administration.
- Patients receiving Etan plus Azil demonstrated superior clinical outcomes compared to those on Etan plus placebo.
Conclusions:
- Azilsartan, by blocking the RAS, may enhance the therapeutic effects of etanercept in managing active RA.
- This combination therapy shows promise for patients with RA refractory to methotrexate.
- Targeting the RAS alongside anti-TNF therapy could be a viable strategy for improving RA treatment.
Related Concept Videos
Pilot and Numeric Relaying
Pharmacodynamics in Geriatric Patients: Effects of Age
Bioavailability Study Design: Healthy Subjects Versus Patients
Biological Effects of Radiation
Buffer Effectiveness
The buffer capacity is the amount of acid or base that can be added to a given volume...
Framing Effects

